Clinical Trials Contact

About this Clinical Trial

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Your Message Will Go To

Valerie Musgrave

650-725-1647


All fields are required. *

Preferred contact method*

To:

Valerie Musgrave

650-725-1647



Go Back To The Trial

We were not able to send your contact info at this time.

Go Back To The Trial